Q-Sphera has clinically demonstrated enhanced bio-delivery and bio-distribution of medicines and has the potential to be applied across a range of therapeutic areas.
Biodexa Pharmaceuticals is developing an internal pipeline of pre-clinical programs in areas of high market value and unmet clinical need. We also operate a collaboration model to enable application of the Q-Sphera platform to our partners’ portfolios, both for on-market and pre-approval drugs. Through partnership Q-Sphera has the potential to add value far beyond our own internal pipeline:
- Optimise clinical solutions
- Repurpose to new indications
- Improve health economics
- Reduce production cost
- Extend IP life-cycle